#ASCO14 - Poster: Time to chemotherapy following treatment with sipuleucel-T: Data from PROCEED

CHICAGO, IL USA (UroToday.com) - Presented by Pieczonka CM,1 Concepcion RS,2 Tutrone RF,3 Penson DF,4 Bailen JL,5 Olsson CA,6 Forrest JB,7 Kassabian V,8 Mehlhaff BA,9 Shore ND,11 Lance RS,11 Tyler RC,12 Sandler A,12 McCoy C,12 Whitmore JB,12 and Cooperberg MR13 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 pieczonka 5040 thumb

Click HERE to listen to an interview with Christopher Pieczonka, MD, one of the authors of the study

1Associated Medical Professionals, Syracuse, NY, USA; 2Urology Associates, P.C., Nashville, TN, USA; 3Chesapeake Urology Research Associates, Baltimore, MD, USA; 4Vanderbilt-Ingram Cancer Center, Nashville, TN, USA; 5First Urology Clinical Research, Jeffersonville, IN, USA; 6Integrated Medical Professionals, Columbia University Medical Center, North Hills, NY, USA; 7Urologic Specialists of Oklahoma, Inc., Tulsa, OK, USA; 8Georgia Urology, Atlanta, GA, USA; 9Oregon Urology Institute, Springfield, OR, USA; 10Carolina Urologic Research Center, Myrtle Beach, SC, USA; 11Urology of Virginia, Norfolk, VA, USA; 12Dendreon Corporation, Seattle, WA, USA; 13University of California San Francisco, San Francisco, CA, USA